ARROW INTERNATIONAL INC - 10-Q Quarterly Report

Back to GetFilings.com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

---------

FORM 10-Q

(X) Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

For the quarterly period ended November 30, 2004

or

( ) Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

For the transition period from ____________ to ____________

Commission File Number 0-20212

ARROW INTERNATIONAL, INC.
-------------------------
(Exact Name of Registrant as Specified in Its Charter)

Pennsylvania 23-1969991
- ------------------------- -----------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)

2400 Bernville Road, Reading, Pennsylvania 19605
- ------------------------------------------ ------
(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: (610) 378-0131
--------------

Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes _X_ No ___

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). Yes _X_ No ___

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

Class Shares Outstanding at January 4, 2005
- ------- -------------------------------------

Common Stock, No Par Value 44,044,868

ARROW INTERNATIONAL, INC.

Form 10-Q Index

Page
----

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

Consolidated Balance Sheets at November 30, 2004
and August 31, 2004 3-4

Consolidated Statements of Income 5

Consolidated Statements of Cash Flows 6-7

Consolidated Statements of Comprehensive
Income 8

Notes to Consolidated Financial Statements 9-16

Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 17-24

Item 3. Quantitative and Qualitative Disclosures About
Market Risk 24-25

Item 4. Controls and Procedures 25

PART II. OTHER INFORMATION

Item 5. Other Information 25-26

Item 6. Exhibits and Reports on Form 8-K 26

Signature 27

Exhibit Index 28

Certifications 29-32

(2)

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

ARROW INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS

(In thousands)
(Unaudited)

November 30, August 31,
2004 2004
------------------------ -----------------------

ASSETS
Current assets:
Cash and cash equivalents $ 95,255 $ 94,176
Accounts receivable, net 88,981 83,918
Inventories 101,133 96,084
Prepaid expenses and other 10,762 7,336
Deferred income taxes 8,265 8,562
------------------------ -----------------------
Total current assets 304,396 290,076
------------------------ -----------------------

Property, plant and equipment 315,666 302,978

Less accumulated depreciation (173,595) (166,000)
------------------------ -----------------------
142,071 136,978
------------------------ -----------------------

Goodwill 42,800 42,698
Intangible assets, net 44,405 40,440
Other assets 10,162 9,889
Prepaid pension costs 32,742 29,127
------------------------ -----------------------
Total other assets 130,109 122,154
------------------------ -----------------------

Total assets $ 576,576 $ 549,208
======================== =======================

See accompanying notes to consolidated financial statements

Continued

(3)

ARROW INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)
(Unaudited)

November 30, August 31,
2004 2004
--------------------------- ------------------------

LIABILITIES

Current liabilities:
Current maturities of long-term debt $ 3,027 $ 3,036
Notes payable 27,873 26,020
Accounts payable 18,412 14,791
Cash overdrafts 1,182 1,136
Accrued liabilities 16,847 16,453
Accrued compensation 12,470 14,171
Accrued income taxes 9,371 4,867
--------------------------- ------------------------
Total current liabilities 89,182 80,474
--------------------------- ------------------------
Long-term debt - -
Accrued postretirement benefit obligations 15,680 15,327

Deferred income taxes 6,844 7,076

Commitments and contingencies

SHAREHOLDERS' EQUITY

Preferred stock, no par value;
5,000,000 shares authorized;
none issued - -

Common stock, no par value;
100,000,000 shares authorized;
52,957,626 shares issued 45,661 45,661

Additional paid-in capital 15,303 12,771

Retained earnings 453,004 443,676

Less treasury stock at cost:
9,012,691 and 9,182,802 shares,
respectively (59,144) (60,261)
Accumulated other comprehensive
income 10,046 4,484
--------------------------- ------------------------
Total shareholders' equity 464,870 446,331
--------------------------- ------------------------
Total liabilities and
shareholders' equity $ 576,576 $ 549,208
=========================== ========================

See accompanying notes to consolidated financial statements

(4)

ARROW INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except share and per share amounts)
(Unaudited)

For the three months ended
--------------------------------------------------
November 30, November 30,
2004 2003
------------------------ ----------------------

Net sales $ 112,725 $ 103,101
Cost of goods sold 56,305 48,903
------------------------ ----------------------
Gross profit 56,420 54,198
------------------------ ----------------------

Operating expenses:
Research and development 7,919 6,844
Selling, general and administrative 28,722 25,738
Restructuring charge 391 -
------------------------ ----------------------
Operating income 19,388 21,616
------------------------ ----------------------
Other expenses (income):
Interest expense, net of amount capitalized 90 199
Interest income (215) (90)
Other, net (166) 139
------------------------ ----------------------
Other expenses (income), net (291) 248
------------------------ ----------------------
Income before income taxes 19,679 21,368
Provision for income taxes 6,396 6,944
------------------------ ----------------------

Net income $ 13,283 $ 14,424
======================== ======================

Basic earnings per common share $ 0.30 $ 0.33
======================== ======================
Diluted earnings per common share $ 0.30 $ 0.33
======================== ======================
Cash dividends per common share $ 0.090 $ 0.080
======================== ======================

Weighted average shares outstanding
used in computing basic earnings
per common share 43,835,821 43,343,619
======================== ======================

Weighted average shares outstanding
used in computing diluted earnings
per common share 44,526,195 43,982,988
======================== ======================

See accompanying notes to consolidated financial statements

(5)

ARROW INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)
(Unaudited)

For the three months ended
---------------------------------------
November 30, November 30,
2004 2003
----------------- -----------------

Cash flows from operating activities:
Net income $ 13,283 $ 14,424
Adjustments to reconcile net income to
net cash provided by operating activities:
Depreciation 5,077 4,423
Amortization 1,382 1,253
401(k) plan stock contribution 241 217
Deferred income taxes 57 517
Loss (gain) on sale of property, plant and equipment 120 20
Increase in provision for postretirement benefit obligation 353 568
(Increase) decrease in prepaid pension costs (3,614) 587
Changes in operating assets and liabilities, net of effects from acquisition:
Accounts receivable, net (1,156) (2,014)
Inventories (123) (51)
Prepaid expenses and other (3,168) (3,370)
Accounts payable and accrued liabilities (1,380) 4,670
Accrued compensation (1,992) (1,812)
Accrued income taxes 5,055 4,673
----------------- -----------------
Total adjustments 852 9,681
----------------- -----------------
Net cash provided by operating activities 14,135 24,105
----------------- -----------------

Cash flows from investing activities:
Capital expenditures (7,105) (4,441)
Proceeds from sale of property, plant and equipment 13 58
(Increase) decrease in intangible and other assets (211) 43
Cash paid for business acquired (4,874) -
----------------- -----------------
Net cash used in investing activities (12,177) (4,340)
----------------- -----------------

Cash flows from financing activities:
(Decrease) in notes payable, including both drawdowns and repayments (533) (2,452)
Reduction of current maturities of long-term debt (9) (498)
Increase (decrease) in book overdrafts 46 (376)
Dividends paid (3,940) (3,462)
Proceeds from stock options exercised 2,461 2,030
----------------- -----------------
Net cash used in financing activities (1,975) (4,758)
----------------- -----------------

Effects of exchange rate changes on cash
and cash equivalents 1,096 966
Net change in cash and cash equivalents 1,079 15,973
Cash and cash equivalents at beginning of year 94,176 46,975
----------------- -----------------
Cash and cash equivalents at end of period $ 95,255 62,948
================= =================

See accompanying notes to consolidated financial statements
Continued

(6)

ARROW INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS, continued

(In thousands)
(Unaudited)

For the three months ended
------------------------------------------------
November 30, November 30,
2004 2003
--------------------- ----------------------

Supplemental schedule of noncash investing and financing activities:

The Company assumed liabilities in conjunction with the purchase of certain
assets as follows:

Estimated fair value of assets acquired $ 8,361 $ -
Accrual for additional payments owed 3,487 -
--------------------- ----------------------
Cash paid for assets $ 4,874 $ -
===================== ======================

Cash paid for business acquired:
Working capital $ 3,008 $ -
Intangible assets 5,353 -
Accrual for additional payments owned (3,487) -
--------------------- ----------------------
$ 4,874 -
===================== ======================

===================== ======================
Dividends declared but not paid $ 3,955 $ 3,474
===================== ======================

See accompanying notes to consolidated financial statements

(7)

ARROW INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)
(Unaudited)

For the three months ended
----------------------------------------
November 30, November 30,
2004 2003
----------------- -------------------

Net income $ 13,283 $ 14,424
Other comprehensive income
Foreign currency translation adjustments 5,562 4,419
----------------- -------------------
Other comprehensive income 5,562 4,419
----------------- -------------------
Total comprehensive income $ 18,845 $ 18,843
================= ===================

See accompanying notes to consolidated financial statements

(8)

ARROW INTERNATIONAL, INC.
Notes to Consolidated Financial Statements

(In thousands, except per share amounts)
(Unaudited)

Note 1 - Basis of Presentation:

These unaudited consolidated financial statements include all adjustments,
consisting only of normal recurring accruals, which management considers
necessary for a fair presentation of the consolidated financial position,
results of operations, and cash flows of Arrow International, Inc. (the
"Company") for the interim periods presented. Results for the interim periods
are not necessarily indicative of results for the entire year. Such statements
are presented in accordance with the requirements of Form 10-Q and do not
include all disclosures normally required by generally accepted accounting
principles or those normally made on Form 10-K. These statements should be read
in conjunction with the consolidated financial statements and notes thereto
contained in the Company's Annual Report to Stockholders for the fiscal year
ended August 31, 2004.

Note 2 - Inventories:

Inventories are summarized as follows:

November 30, 2004 August 31, 2004
---------------------- ----------------------
Finished goods $ 29,127 $ 29,036
Semi-finished goods 28,722 26,126
Work-in-process 10,239 9,493
Raw materials 33,045 31,429
---------------------- ----------------------
$ 101,133 $ 96,084
====================== ======================

Note 3 - Commitments and Contingencies:

The Company is a party to certain legal actions, including product liability
matters, arising in the ordinary course of its business. From time to time, the
Company is also subject to legal actions involving patent and other intellectual
property claims.

The Company is currently a defendant in a lawsuit in which the plaintiff alleges
that the Company's Cannon-Cath(TM) split-tip hemodialysis catheters, which were
acquired as part of the Company's acquisition in November 2002 of specified
assets of Diatek, Inc., infringe a patent owned by or licensed to the
plaintiffs. In November 2003, this lawsuit was stayed pending the U.S. Patent
and Trademark Office's ruling on its re-examination of the patent at issue,
which is expected to occur in calendar 2005, although the Company cannot
presently predict the precise timing. Based on information presently available
to the Company, the Company believes that its products do not infringe any valid
claim of the plaintiff's patent and that, consequently, it has meritorious legal
defenses with respect to this action.

Although the ultimate outcome of any of these actions is not expected to have a
material adverse effect on the Company's business or financial condition,
whether an adverse outcome in any of these actions would materially adversely
affect the Company's reported results of operations in any future period cannot
be predicted with certainty.

Note 4 - Accounting Policies:

As permitted under SFAS No. 123, the Company continues to apply the existing
accounting rules under Accounting Principles Board (APB) No. 25, as amended by
SFAS No. 148, and provide pro forma net income and pro forma earnings per share
disclosures for employee stock option grants made as if the fair value method in
measuring compensation costs for stock options granted subsequent to December
15, 1995 had been applied.

Had compensation expense for stock options granted in fiscal 2005 and 2004 been
recorded based on the fair market value at the grant date, the Company's net
income and basic and diluted earnings per share, net of related income tax
effects, for the periods ended November 30, 2004 and 2003 would have been
reduced to the pro forma amounts indicated in the table below:

(9)

ARROW INTERNATIONAL, INC.
Notes to Consolidated Financial Statements

(In thousands, except per share amounts)
(Unaudited)

For the three months ended
--------------------------------------------
November 30, 2004 November 30, 2003
------------------- -------------------

Net income applicable to common shareholders
As reported $ 13,283 $ 14,424
Deduct: Total stock-based employee compensation
expense determined under fair value based method for all
awards, net of related tax effects (408) (653)
Pro forma $ 12,875 $ 13,771

Basic earnings per common share
As reported $ 0.30 $ 0.33
Pro forma $ 0.29 $ 0.32

Diluted earnings per common share
As reported $ 0.30 $ 0.33
Pro forma $ 0.29 $ 0.31

The pro forma effects are not representative of the effects on reported net
income for future years, as most of the stock option awards granted by the
Company vest in cumulative increments over a period of either four or five
years. The information provided in the table above includes the impact of both
vested and non-vested options.

Accounts Receivable and Allowance for Doubtful Accounts:
Trade accounts receivable are recorded at the invoiced amount and do not bear
interest. The Company maintains an allowance for doubtful accounts for estimated
losses resulting from the inability of our customers to make required payments.
This allowance is used to state trade receivables at estimated net realizable
value. The Company relies on prior payment trends while giving consideration to
other criteria such as political risk, financial status and other factors to
estimate the cash which ultimately will be received. Such amounts cannot be
known with certainty at the financial statement date. The Company regularly
reviews individual past due balances over 90 days and over a specific amount for
collectability and maintains a specific allowance for customer accounts that
will likely not be collectible due to customer liquidity issues. The Company
also maintains an allowance for estimated future collection losses on existing
receivables, determined based on historical trends.

The following are the changes in the allowance for doubtful accounts for the
three months ended November 30, 2004 and 2003:

For the three months ended
--------------------------------------------
November 30, 2004 November 30, 2003
------------------- -------------------
Balance at September 1 $ 2,198 $ 1,112
Additions 178 (51)

Write-offs net of recoveries (772) (65)
------------------- -------------------
Balance at November 30 $ 1,604 $ 996
=================== ===================

The Company has disclosed in Note 1 to its consolidated financial statements
included in its Annual Report on Form 10-K for the fiscal year ended August 31,
2004 those accounting policies that it considers to be significant in
determining its results of operations and financial position. There have been no
material changes to the critical accounting policies previously identified and
described in the Company's 2004 Form 10-K. The accounting principles utilized by
the Company in preparing its consolidated financial statements conform in all
material respects to generally accepted accounting principles in the United
States of America.

The preparation of these consolidated financial statements requires the
Company's management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, revenues and expenses, as well as the disclosure
of contingent assets and liabilities at the date of its financial statements.
The Company bases its estimates on historical experience, actuarial valuations
and various other factors that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from
other sources. Some of those judgments

(10)

ARROW INTERNATIONAL, INC.
Notes to Consolidated Financial Statements

(In thousands, except per share amounts)
(Unaudited)

can be subjective and complex and, consequently, actual results may differ from
these estimates under different assumptions or conditions. While for any given
estimate or assumption made by the Company's management there may be other
estimates or assumptions that are reasonable, the Company believes that, given
the current facts and circumstances, it is unlikely that applying any such other
reasonable estimate or assumption would materially impact the financial
statements.

Certain prior period information has been reclassified for comparative purposes.

Note 5 - Segment Reporting:

SFAS No. 131, "Disclosures about Segments of an Enterprise and Related
Information", requires the reporting of certain financial information for each
operating segment. The Company has one operating segment as defined in this
standard based on the fact that its various business components do not possess
the defined characteristics that would meet the standard's definition of
operating segments. For instance, the Company's current management structure is
designed to operate the business as a whole, with no divisional
responsibilities. Therefore, the Company continues to operate as a single
operating segment. The Company operates in four main geographic regions,
therefore, information about products and geographic areas is presented below.

The following table provides quarterly information about the Company's sales by
product category:

Quarter ended Quarter ended
November 30, 2004 November 30, 2003
------------------------------------ --------------------------------------
Critical Cardiac Critical Cardiac
Care Care Care Care
---------------- ----------------- ----------------- -----------------

Sales to external customers $96,000 $16,700 $89,000 $14,100

The following tables present quarterly information about geographic areas:

Quarter ended November 30, 2004
--------------------------------------------------------------------------------------
United Asia and Other
States Africa Europe Foreign Consolidated
------------- ------------- -------------- ------------ -------------------

Sales to unaffiliated
customers $68,700 $17,700 $20,000 $6,300 $112,700

Quarter ended November 30, 2003
--------------------------------------------------------------------------------------
United Asia and Other
States Africa Europe Foreign Consolidated
------------- ------------- -------------- ------------ -------------------
Sales to unaffiliated
customers $67,200 $15,600 $15,000 $5,300 $103,100

Note 6 - New Accounting Standards:

The Financial Accounting Standards Board (FASB) issued Statement of Financial
Accounting Standards (SFAS) No. 151, "Inventory Costs, an Amendment of
Accounting Research Bulletin (ARB) No. 43, Chapter 4", in November 2004. This
statement amends the guidance in ARB No. 43 Chapter 4 "Inventory Pricing" to
clarify the accounting for abnormal amounts of idle facility expense, freight,
handling costs and wasted material. SFAS No. 151 requires that those items be
recognized as current period charges regardless of whether they meet the
criterion of "so abnormal." In addition, this statement requires that allocation
of fixed production overheads to the costs of conversion be based on the normal
capacity of the production facilities. The provisions of this statement will be
effective for inventory costs incurred during fiscal years beginning after June
15, 2005. The Company is currently evaluating the impact that this statement
will have on its financial statements.

The FASB issued "Share-Based Payment, an Amendment of SFAS No. 123 and 95", in
December 2004. This statement requires that the cost of all forms of
equity-based compensation granted to employees, excluding employee stock
ownership plans, be recognized in a company's income statement and that such
cost be measured at the fair value of the stock options. This statement replaces
the

(11)

ARROW INTERNATIONAL, INC.
Notes to Consolidated Financial Statements

(In thousands, except per share amounts)
(Unaudited)

guidance in SFAS No. 123, Accounting for Stock-Based Compensation, and APB No.
25, Accounting for Stock Issued to Employees. This statement will be effective
for financial statements relating to fiscal periods beginning after June 15,
2005.

Note 7 - Business Acquisitions:

In September 2004, the Company purchased certain assets of one of its
distributors in Italy, AB Medica S.p.A. (ABM), for a total purchase price of
approximately $8,361, subject to post-closing adjustments, with additional
amounts payable contingent upon the sales levels of products under sales
contracts purchased by the Company. ABM had been one of the Company's
distributors in Italy since 1982. The asset purchase agreement includes the
purchase of customer lists, distributorship rights, as well as the inventory and
specified tender contracts associated with the sale by ABM of the Company's
products. The Company began selling directly in Italy through its subsidiary,
Arrow Italy S.p.A., in the first quarter of fiscal 2005. As of November 30,
2004, pursuant to the asset purchase agreement, the Company has paid $4,874 in
cash and recorded a current liability of $3,487 for additional payment
installments, of which $2,090 was paid in December 2004. The purchase price for
this acquisition did not exceed the estimated fair value of the net assets
acquired and, therefore, no goodwill has been recorded by the Company in
connection therewith. Intangible assets acquired of $5,353, consisting of
customer lists and distributorship rights, are being amortized over five years
based on the anticipated period over which the Company expects to benefit from
the transaction. Included in the first quarter of fiscal 2005 was a $1,467
charge, or $990 against net income, for the step-up of inventory purchased from
ABM. The results of operations of this business are included in the Company's
consolidated financial statements from the date of acquisition. The purchase
price for this acquisition was allocated as follows:

Inventories $ 3,008
Intangible assets 5,353
-----------
Total purchase price $ 8,361
===========

Pro forma amounts are not presented as the acquisition described above did not
have any material effect on the Company's results of operations or financial
condition for any of the periods presented.

Note 8 - Stock Option Plans:

The Company has adopted three stock plans, the 1992 Stock Incentive Plan (the
"1992 Plan"), which was adopted on April 1, 1992, the Directors' Stock Incentive
Plan, as amended (the "Directors' Plan"), which was approved by the Company's
shareholders on January 17, 1996, with amendments thereto approved by the
Company's shareholders on January 19, 2000, and the 1999 Stock Incentive Plan
(the "1999 Plan"), which was approved by the Company's shareholders on June 19,
2000, with non-material amendments thereto approved by the Company's Board of
Directors on October 27, 2004. The 1992 and 1999 Plans authorize the granting of
stock options, stock appreciation rights and restricted stock. The Directors'
Plan authorizes the granting of a maximum of 300,000 non-qualified stock
options. Under the Directors' Plan, members of the Board of Directors of the
Company and its subsidiaries are eligible to participate if they are not also
employees or consultants of the Company or its subsidiaries, and do not serve on
the Board of Directors as representatives of the interest of shareholders who
have made an investment in the Company. The Directors' Plan authorizes an
initial grant of an option to purchase 10,000 shares of common stock upon each
eligible director's initial election to the Board of Directors and the grant of
an additional option to purchase 3,000 shares of common stock on the date each
year when directors are elected to the Board of Directors.

The Company follows the provision of APB No. 25, "Accounting for Stock Issued to
Employees", and related interpretations, which require compensation expense for
options to be recognized only if the market price of the underlying stock
exceeds the exercise price on the date of grant. Accordingly, the Company has
not recognized compensation expense for its options granted during the three
months ended November 30, 2004 and November 30, 2003, respectively.

In the three months ended November 30, 2004 and November 30, 2003, the Company
granted 15,000 and 1,240,000 options, respectively, to key employees to purchase
shares of the Company's common stock pursuant to the 1999 Plan. The exercise
price per share was $29.08 for the options granted during the three months ended
November 30, 2004 and ranged from $25.00 to $25.80 for the options granted in
the same period of fiscal 2004. These amounts represent the fair market value of
the common stock of the Company on the respective dates that the options were
granted. The options expire ten years from the grant date. The options vest
ratably over four years, at one year intervals from the grant date and, once
vested, are exercisable at any time.

In the first three months of each of fiscal 2005 and 2004, there were no options
granted by the Company to its directors to purchase shares of the Company's
common stock pursuant to the Directors' Plan.

(12)

ARROW INTERNATIONAL, INC.
Notes to Consolidated Financial Statements

(In thousands, except per share amounts)
(Unaudited)

Stock option activity for the three month periods ended November 30, 2004 and
2003 is summarized in the tables below:

For the three months ended
-------------------------------------------------------------------------------
November 30, 2004 November 30, 2003
--------------------------------------- ------------------------------------
Weighted Weighted
Average Average
Exercise Exercise
Shares Price Shares Price
---------------- ------------------- --------------- -----------------

Outstanding at September 1 3,084,152 $20.49 2,318,260 $16.81
Granted 15,000 $29.08 1,240,000 $25.26
Exercised (171,818) $15.40 (132,190) $15.39
Terminated (59,140) $21.77 (20,150) $17.77
---------------- ---------------

Outstanding at November 30 2,868,194 $20.82 3,405,920 $19.94

Exercisable at November 30 1,536,887 $18.47 1,359,778 $16.25

Stock options outstanding at November 30, 2004 are summarized in the table
below:

Weighted Weighted Weighted
Average Average Average
Range of Number Remaining Exercise Number Exercise
Exercise Prices Outstanding Contractual Life Price Exercisable Price
- -------------------------- --------------- -------------------- ------------- -------------- ---------------

$12.56 - $17.50 563,934 4.10 $14.42 563,934 $14.42
$17.51 - $21.47 1,058,422 6.23 $18.90 674,493 $18.86
$21.48 - $26.42 1,230,838 8.82 $25.29 298,460 $25.27
$26.43 - $29.08 15,000 9.92 $29.08 - -

The Company has adopted the disclosure provisions of SFAS No. 123, "Accounting
for Stock-Based Compensation". As permitted under SFAS No.123, the Company
continues to apply the existing accounting rules under APB No. 25 and provide
pro forma net income and pro forma earnings per share disclosures for employee
stock option grants made as if the fair value method in measuring compensation
cost for stock options granted subsequent to December 15, 1995 had been applied.

The per share weighted average value of stock options granted in the first three
months of fiscal 2005 and 2004 was $5.15 and $10.56, respectively. The fair
value was estimated as of the grant date using the Black-Scholes option pricing
model with the following average assumption:

November November
30, 2004 30, 2003
--------------------- --------------------
Risk-free interest rate 2.58% 2.58%
Dividend yield 1.33% 1.33%
Volatility factor 20.86% 44.02%
Expected lives 4 years 5 years

(13)

ARROW INTERNATIONAL, INC.
Notes to Consolidated Financial Statements

(In thousands, except per share amounts)
(Unaudited)

Note 9 - Warranty

The Company's primary warranty obligation relates to sales of its intra-aortic
balloon pumps. The Company offers a warranty of one year to its U.S. customers
and two years to its international customers. As of November 30, 2004, the
Company's total estimated product warranty obligation is $659. Because this
estimate is based primarily on historical experience, actual costs may differ
from the amounts estimated. The change in the warranty obligation for the three
months ended November 30, 2004 is as follows:

Balance as of September 1, 2004 $ 740
Additional warranties issued 229
Expenditures (310)
------------
Balance as of November 30, 2004 $ 659
============

Note 10 - Retirement Benefits

Pension Plans:

The Company has three noncontributory pension plans that cover substantially all
employees. Benefits under the plans are based upon an employee's compensation
and years of service and, where applicable, the provisions of negotiated labor
contracts. It is the Company's policy to make contributions to these plans
sufficient to meet the minimum funding requirements of applicable laws and
regulations plus such additional amounts, if any, as the Company's actuarial
consultants advise to be appropriate. The projected unit credit method is
utilized for determination of actuarial amounts.

Plan assets consist principally of U.S. government securities, short-term
investments, other equity securities and cash equivalents.

On September 1, 2000, the Company established a Defined Benefit Supplemental
Executive Retirement Plan to provide pension benefits to selected executives and
retired executives/directors of the Company. The plan is unfunded and the
benefits provided under the plan are intended to be in addition to other
employee retirement benefits offered by the Company, including but not limited
to tax-qualified employee retirement plans.

Postretirement Benefits Other Than Pensions:

The Company provides limited amounts of postretirement health and life insurance
benefit plan coverage for some of its employees. The determination of the cost
of postretirement health benefit plans is based on comprehensive hospital,
medical, surgical and dental benefit provisions ("Other Benefits"). The
determination of the cost of postretirement life insurance benefits is based on
stated policy amounts.

The following summarizes the components of the net periodic benefit costs for
the three months ended November 30, 2004 and 2003:

Pension Benefits Other Benefits
------------------------------------ ------------------------------------
For the Three Months Ended For the Three Months Ended
------------------------------------ ------------------------------------
November 30, November 30, November 30, November 30,
2004 2003 2004 2003
---------------- ---------------- ---------------- ----------------

Service cost $ 885 $ 822 $ 111 $ 103
Interest cost 1,361 1,214 259 210
Expected return on plan
assets (1,803) (1,703) - -
Amortization of prior
service costs 302 228 (40) (23)
Amortization of transition
obligation (asset) (36) (26) 13 13
Amortization of net
actuarial (gain) loss 279 213 53 47
Plan acquisition
differential - 38 (7) (8)
---------------- ---------------- ---------------- ----------------
Net periodic (benefit)
cost $ 988 $ 786 $ 389 $ 342
================ ================ ================ ================

(14)

ARROW INTERNATIONAL, INC.
Notes to Consolidated Financial Statements

(In thousands, except per share amounts)
(Unaudited)

Note 11 - Restructuring Charges:

In August 2004, the Company initiated the consolidation of its operations at its
Winston-Salem, North Carolina and San Antonio, Texas facilities into other
existing manufacturing facilities. These steps are part of the Company's overall
manufacturing realignment and capacity increases announced in June 2004. The
transitional work on the consolidation has begun and the consolidation is
expected to continue into the spring of 2005. In connection with this
restructuring, the Company has accrued costs of $240, consisting primarily of
severance payments, in the first quarter of fiscal year 2005. Severance payments
relate to approximately 53 employees primarily in manufacturing and are expected
to be paid over the remainder of fiscal 2005. As of November 30, 2004, the
Company has made $51 of severance payments in connection with this
consolidation. All other restructuring costs are expected to be paid over the
remainder of fiscal 2005 and fiscal 2006. Restructuring charges related to this
manufacturing realignment are summarized in the table below:

Actual Costs Expensed
----------------------------------------------------
Estimate of For the Twelve For the Three Estimated
Total Expected Months Ended Months Ended Costs yet
Restructuring August 31, November 30, Total to to be
Charges 2004 2004 Date Expensed
------------------ ----------------- ---------------- ----------- -------------

Severance and related
expenses $ 642 $ 208 $ 184 $ 392 $ 250
Property, plant and
equipment carrying
cost and costs of
disposal 370 - 48 48 322
Other, including
equipment and
inventory moving costs,
employee relocation
costs, and external
consulting fees 201 - 8 8 193
------------------ ----------------- ---------------- ----------- -------------
Total restructuring
charges $ 1,213 $ 208 $ 240 $ 448 $ 765
================== ================= ================ =========== =============

As part of its plans to rationalize its production operations in Europe, in
November 2004, the Company determined to move its European Distribution Center,
currently situated in Weesp, Netherlands, to a more centralized European
location in the Limberg region of Belgium in order to have better access to
existing carrier transportation networks and allow for more cost-competitive
expansion of its European operations in the future. The Company anticipates that
this relocation will be completed in the second quarter of fiscal 2005 and will
cost approximately $1,543. As of November 30, 2004, the Company has accrued
severance payments of $151 related to this re-location, which amount represents
total actual restructuring costs incurred during the first quarter of fiscal
2005. As of November 30, 2004, the Company has not made any severance payments
in connection with this consolidation. Restructuring charges related to this
distribution center re-location are summarized below:

Actual Costs Expensed
----------------------------------------------------
Estimate of For the Twelve For the Three Estimated
Total Expected Months Ended Months Ended Costs yet
Restructuring August 31, November 30, Total to to be
Charges 2004 2004 Date Expensed
------------------ ----------------- ---------------- ----------- -------------

Severance and related
expenses $ 495 - $ 151 $ 151 $ 344
Lease termination costs 295 - - - 295
Property, plant and
equipment carrying cost
and costs of disposal 175 - - - 175
Other, including
equipment and
inventory moving costs,
employee relocation
costs, and external
consulting fees 495 - - - 495
------------------ ----------------- ---------------- ----------- -------------
Total restructuring
charges $ 1,460 - $ 151 $ 151 $ 1,309
================== ================= ================ =========== =============

(15)

ARROW INTERNATIONAL, INC.
Notes to Consolidated Financial Statements

(In thousands, except per share amounts)
(Unaudited)

Note 12 - Earnings Per Share

The following is a reconciliation of weighted average common shares outstanding
assuming dilution used in the calculation of earnings per share for the three
months ended November 30, 2004 and 2003:

For the Three For the Three
Months Ended Months ended
November 30, November 30,
2004 2003
--------------------- -------------------

Net income $13,283 $14,424

Weighted average common shares outstanding 43,836 43,344

Incremental common shares issuable: stock options
and awards 690 639
--------------------- -------------------

Weighted average common shares outstanding
assuming dilution 44,526 43,983
===================== ===================

Basic earnings per common share $0.30 $0.33
===================== ===================

Diluted earnings per common share $0.30 $0.33
===================== ===================

Stock options outstanding to purchase 15,000 and 0 shares of common stock were
not included in the computation of earnings per share assuming dilution because
the options' exercise prices were greater than the average market price of the
Company's common stock at November 30, 2004 and 2003, respectively.

Note 13 - Subsequent Event

On December 3, 2004, the Company announced that, after consulting with the U.S.
Food and Drug Administration (the "FDA"), it was voluntarily initiating a
nationwide recall of all of its NEO?PICC(R) 1.9 FR Peripherally Inserted Central
Catheters (the "NeoPICC Catheters") as a result of having received several
reports of adverse events involving the utilization of the NeoPICC Catheters.
The NeoPICC Catheter is part of the Company's NEOCare product line of catheters
and related procedure kits for neonatal intensive care that it acquired from
Klein Baker Medical, Inc. in March 2003. The Company is cooperating with the FDA
in conducting the voluntary recall. As of January 7, 2005, the Company has not
received any product liability claims in connection with the product recall.

The Company sent recall notices to approximately 800 hospitals and 16 dealers,
but is unable at the present time to determine the precise number of NeoPICC
Catheters that will be returned by customers in response to this voluntary
recall or the potential effect the recall may have on its business or future
results of operations. In the first quarter of fiscal 2005, the Company recorded
a charge against net sales of $500, representing its issued sales credits as of
January 7, 2005 and an estimate for those sales credits yet to be issued
relating to returned NeoPICC Catheters.

Following the recall, the FDA inspected the Company's corporate headquarters and
the facility where the NeoPICC Catheters are manufactured and provided the
Company with a list of inspectional observations. The Company is reviewing these
observations and how best to address them. As part of its previously announced
plans to rationalize its global manufacturing and logistics operations, the
Company has decided to accelerate the integration of the NEOCare manufacturing
operations into its existing manufacturing structure. In order to facilitate
this integration of NEOCare and to address each of the inspectional observations
of the FDA, the Company has temporarily ceased the manufacture, shipment and
sales of its NEOCare product line, including the NeoPICC Catheters, until it has
adequately addressed each of the inspectional observations. Shipment of the
NeoPICC Catheters will resume after receipt of FDA clearance of a new 510(k)
premarket notification for these products. Shipments of the NEOCare product
line, other than the NeoPICC Catheters, are expected to resume within the next
three to four months.

The Company's fiscal 2004 NEOCare product line sales were $7,646. Inventories
of NeoPICC Catheters at November 30, 2004 amounted to $172, which the Company
fully reserved for in the first quarter of fiscal 2005. Inventories of other
NEOCare products were approximately $1,509 at November 30, 2004.

(16)

ARROW INTERNATIONAL, INC.

Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations

THE FOLLOWING DISCUSSION INCLUDES CERTAIN FORWARD-LOOKING STATEMENTS. SUCH
FORWARD-LOOKING STATEMENTS ARE SUBJECT TO A NUMBER OF FACTORS, INCLUDING
MATERIAL RISKS, UNCERTAINTIES AND CONTINGENCIES, WHICH COULD CAUSE ACTUAL
RESULTS TO DIFFER MATERIALLY FROM THE FORWARD-LOOKING STATEMENTS. FOR A
DISCUSSION OF IMPORTANT FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER
MATERIALLY FROM THE FORWARD-LOOKING STATEMENTS, SEE ITEM 1. BUSINESS - CERTAIN
RISKS RELATING TO ARROW IN THE COMPANY'S ANNUAL REPORT ON FORM 10-K FOR THE
FISCAL YEAR ENDED AUGUST 31, 2004 AND THE COMPANY'S OTHER PERIODIC REPORTS AND
DOCUMENTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

RESULTS OF OPERATIONS

Three Months Ended November 30, 2004 Compared to Three Months Ended November 30,
2003

NET SALES.
Net sales for the three months ended November 30, 2004 increased by $9.6
million, or 9.3%, to $112.7 million from $103.1 million in the same period of
last year due primarily to an increase in critical care product sales and a
favorable foreign exchange impact during the first quarter of fiscal 2005 as a
result of the weakness of the U.S. dollar relative to currencies of countries in
which the Company operates direct sales subsidiaries. This foreign exchange
impact resulted in increased sales for the quarter of $1.9 million or 1.8% of
total Company sales. Net sales represent gross sales invoiced to customers, less
certain related charges, discounts, returns and rebates. Revenue from sales is
recognized at the time products are shipped and title is passed to the customer.
The following is a summary of the Company's sales by product platform:

Sales by Product Platform
(in millions) Quarter ended
November 30, 2004 November 30, 2003
----------------- -----------------

Central Venous Catheters $ 59.3 $ 53.6
Specialty Catheters 34.8 32.3
Stepic distributed products 1.9 3.1
------ ------
Subtotal Critical Care 96.0 89.0
Cardiac Care 16.7 14.1
------ ------
TOTAL $112.7 $103.1
====== ======

Sales of critical care products increased 7.9% to $96.0 million in the first
quarter of fiscal 2005 from $89.0 million in the comparable prior year period
due primarily to increased sales of central venous and specialty catheters
offset by decreased sales of products distributed by Stepic Medical, the
Company's former New York City distributor, the net assets of which it acquired
in September 2002. Sales of central venous catheters increased in the first
quarter of fiscal 2005 due primarily to a continued increase in the number of
hospitals that are purchasing the Company's procedure kits featuring its safety
devices and ARROWg+ard(R) antiseptic surface treatments, as well as increased
sales of renal access products. Sales of specialty catheters increased in the
first quarter of fiscal 2005 due to improved sales of arterial products,
intravenous and extension sets, and epidural products. Sales of cardiac care
products increased by 18.4% to $16.7 million in the first quarter of fiscal 2005
from $14.1 million in the comparable prior year period due primarily to
increased international sales of intra-aortic balloon pumps and Super
Arrow-Flex(R) products. Total Company U.S. sales increased 2.2% to $68.7 million
from $67.2 million in the prior year period due primarily to increased sales of
central venous and specialty catheters. International sales increased by 22.6%
to $44.0 million in the first quarter of fiscal 2005 from $35.9 million in the
comparable prior year period principally as a result of increased sales of
central venous catheters, specialty catheters, intra-aortic balloon pumps and
Super Arrow-Flex(R) products, and the effect of foreign currency exchange rates,
as noted above. International sales represented 39.0% of net sales in the first
quarter of fiscal 2005 compared to 34.8% in the same prior year period.

The ARROWg+ard(R) conversion percentages, which are the number of units sold
with the ARROWg+ard(R) antiseptic surface treatments as a percentage of the
Company's total multilumen and hemodialysis unit sales, was 38% of total Company
sales in each of the first quarters of fiscal 2005 and fiscal 2004. The
ARROWg+ard(R) conversion percentages for the U.S. market increased to 64% in the
first quarter of fiscal 2005 from 61% in the comparable prior year period.

The safety device procedure kits conversion percentages, which are the number of
units sold with the Company's procedure kits featuring its safety devices as a
percentage of the total number of units sold of the Company's products that
could potentially include safety device procedure kits, increased to 8% of total
Company sales in the first quarter of fiscal 2005 from 6% in the comparable
prior year period. The safety device procedure kit conversion percentages for
the U.S. market in the first quarter of fiscal 2005 increased to 16% from 12% in
the comparable prior year period.

(17)

ARROW INTERNATIONAL, INC.

GROSS PROFIT.
Gross profit increased 4.1% to $56.4 million in the three months ended November
30, 2004 from $54.2 million in the same period of fiscal 2004. As a percentage
of net sales, gross profit decreased to 50.0% during the three months ended
November 30, 2004 from 52.6% in the comparable prior year period. The decrease
in gross margin was due primarily to: (1) higher manufacturing costs associated
with increased production requirements; (2) lower margins realized in the first
quarter of fiscal 2005 on the sale of inventories of products acquired as part
of the Company's purchase of the net assets of AB Medica, the Company's former
Italian distributor, in September 2004, as further discussed below under
"Liquidity and Capital Resources - Investing Activities"; and (3) unfavorable
inventory adjustments in the first quarter of fiscal 2005.

PRODUCT RECALL.
On December 3, 2004, the Company announced that, after consulting with the FDA,
it was voluntarily initiating a nationwide recall of all of its NEO?PICC(R) 1.9
FR Peripherally Inserted Central Catheters (the "NeoPICC Catheters") as a result
of having received several reports of adverse events involving the utilization
of the NeoPICC Catheters. The NeoPICC Catheter is part of the Company's NEOCare
product line of catheters and related procedure kits for neonatal intensive care
that it acquired from Klein Baker Medical, Inc. in March 2003. The Company is
cooperating with the FDA in conducting the voluntary recall. As of January 7,
2005, the Company has not received any product liability claims in connection
with the product recall.

The Company sent recall notices to approximately 800 hospitals and 16 dealers,
but is unable at the present time to determine the precise number of NeoPICC
Catheters that will be returned by customers in response to this voluntary
recall or the potential effect the recall may have on its business or future
results of operations. In the first quarter of fiscal 2005, the Company recorded
a charge against net sales of $0.5 million, representing its issued sales
credits as of January 7, 2005 and an estimate for those sales credits yet to be
issued relating to returned NeoPICC Catheters.

Following the recall, the FDA inspected the Company's corporate headquarters and
the facility where the NeoPICC Catheters are manufactured and provided the
Company with a list of inspectional observations. The Company is reviewing these
observations and how best to address them. As part of its previously announced
plans to rationalize its global manufacturing and logistics operations, the
Company has decided to accelerate the integration of the NEOCare manufacturing
operations into its existing manufacturing structure. In order to facilitate
this integration of NEOCare and to address each of the inspectional observations
of the FDA, the Company has temporarily ceased the manufacture, shipment and
sales of its NEOCare product line, including the NeoPICC Catheters, until it has
adequately addressed each of the inspectional observations. Shipment of the
NeoPICC Catheters will resume after receipt of FDA clearance of a new 510(k)
premarket notification for these products. Shipments of the NEOCare product
line, other than the NeoPICC Catheters, are expected to resume within the next
three to four months.

The Company's fiscal 2004 NEOCare product line sales were $7.6 million.
Inventories of NeoPICC Catheters at November 30, 2004 amounted to $0.2 million,
which the Company fully reserved for in the first quarter of fiscal 2005.
Inventories of other NEOCare products were approximately $1.5 million at
November 30, 2004.

RESEARCH AND DEVELOPMENT.
Research and development expenses increased by 16.2% to $7.9 million in the
three months ended November 30, 2004 from $6.8 million in the comparable prior
year period. As a percentage of net sales, these expenses increased in the first
quarter of fiscal 2005 to 7.0% compared to 6.6% in the same period in fiscal
2004. The increase in research and development expenses was due primarily to
increased research and development expenditures for the Company's critical care
product line offset in part by (1) decreased research and development spending
on the Arrow Lionheart, the Company's fully implantable Left Ventricular Assist
System (LVAS), which included $1.0 million in the first quarter of fiscal 2005
for development of the LionHeart's second generation electronics, and (2)
decreased research and development spending on the CorAide(TM) continuous flow
ventricular assist system, the Company's joint research and development program
with The Cleveland Clinic Foundation. The current status of the Company's
principal product development programs is summarized below.

AUTOCAT(R)2 WAVE. The Company continues to market and make modifications to its
AutoCAT(R)2 WAVETM intra-aortic balloon pump and associated LightWAVE(TM)
catheter system, which utilizes fiber optic pressure-sensing catheter
instrumentation and provides total automation of the pumping process for all
patients, including those with severely arrhythmic heartbeats. Full market
release of this new technology in the U.S. and Europe is planned for the second
quarter of fiscal 2005. During the first quarter of fiscal 2005, net sales of
the AutoCAT(R)2 WAVETM and related LightWAVE(TM) catheters increased 8.0% over
the fourth quarter of fiscal 2004, as customer response to this product
continues to be positive. The growing interest in this product has resulted in
increased customer feedback, providing the Company with valuable information for
making additional product enhancements. The Company expects to begin market
evaluation of these improvements later in fiscal year 2005. Development of this
product is an ongoing process, with product improvements constantly being made
and introduced as the underlying technology advances and the Company learns more
about customer requirements.

Although the Company is encouraged by the early sales results of its AutoCAT(R)2
WAVETM and related LightWAVE(TM) catheter system, the selling cycle for
intra-aortic balloon pumps is long and involves a number of decision-makers in
any given hospital. As a result, the Company is cautiously optimistic about the
time frame for this product's future sales growth. The Company continues to
believe that this new technology represents a major step forward in intra-aortic
balloon pumping and should enable the Company to gain market share based on
superior performance across a range of cardiac requirements.

LIONHEART(TM) LVAS. The Company has submitted portions of the design dossier for
the second generation LionHeart(TM) power system and controller to the Company's
European Notified Body, TUV Product Services of Munich, Germany. The Company
anticipates all required documentation to be submitted in the first quarter of
calendar year 2005 and receiving approval for use of these electronics in the
device approximately three months later, given that many of its components have
not changed, no additional clinical data is required, and the LionHeart(TM)
quality system has already been certified. Arrow's European marketing plan for
the LionHeart(TM) is based upon the receipt of this approval and the CE-marking
of the second generation electronics.

(18)

ARROW INTERNATIONAL, INC.

As previously reported, the Company decided in the third quarter of fiscal 2004
to defer completion of the LionHeart(TM) Phase I clinical trials and
commencement of the Phase II clinical trials, required by the U.S. Food and Drug
Administration (the "FDA"), to bring the product to market in the U.S., until
the Company is able to implement the second generation product enhancements that
are currently in the testing phase.

The Company's near-term focus for the LionHeart(TM) program continues to be on
obtaining optimal clinical results and on evaluating the second generation
product enhancements currently in development. The Company believes that these
enhancements should increase the patient population for whom the device is
suitable and provide improved quality of life for recipients. The Company does
not expect sales of the LionHeart(TM) to materially impact its fiscal 2005
financial results.

CORAIDE(TM) LVAS. The Company has completed development of modifications to its
CorAide(TM) continuous flow ventricular assist device to resolve elevated levels
of hemolysis (plasma-free hemoglobin) experienced in the first implant of the
device. The Company expects that European clinical trials of the CorAide(TM)
device should resume in fiscal 2005. The cardiac transplant center at Bad
Oyenhausen, Germany is currently screening patients for a suitable candidate.

The Company considers the CorAide(TM) development program to be complementary to
its ongoing program to further develop and market the Arrow LionHeart(TM) LVAS.
The first version of the CorAide(TM) device is not fully implantable and is
intended to provide support for patients waiting for heart transplantation or
considered candidates for bridging to natural recovery of ventricular function.
The Company continues to believe that successful development of the CorAide(TM)
device would provide a lower cost, less invasive and broader application
approach to ventricular assist than pulsatile devices that are currently
available or under development.

As previously reported, the Company has also commissioned a study of its entire
Left Ventricular Assist System program by an outside consulting firm in order to
provide additional perspective on the long-term commercial opportunity for these
products and strategies for maximizing their potential.

HEMOSONIC(TM). During the first quarter of fiscal 2005, the Company continued
its development of an improved version of its HemoSonicTM , a monitoring device
that continuously measures descending aortic blood flow using a non-invasive
esophageal ultrasound probe, that it believes will be more user-friendly and
better able to meet the needs of a broader range of physicians. The Company is
currently in the final stages of this development and expects to begin market
evaluation of the new model later in fiscal 2005. The Company is also currently
in the process of clinically evaluating a number of enhancements to this
product.

SELLING, GENERAL AND ADMINISTRATIVE.
Selling, general and administrative expenses increased by 11.7% to $28.7 million
during the three months ended November 30, 2004 from $25.7 million in the
comparable prior year period and, as a percentage of net sales, increased to
25.5% in the first quarter of fiscal 2005 from 25.0% in the comparable period of
fiscal 2004. This increase was due primarily to: (1) a $1.1 million increase in
expenses related to the Company's international operations as a result of the
weakness of the U.S. dollar relative to currencies of countries in which the
Company operates direct sales subsidiaries; and (2) increased expenses of $0.9
million related to severance costs, increased expenses related to the continued
enhancement of the Company's European Sales office, and increased expenses
related to the initiation of a study by an outside consulting firm of the
Company's Left Ventricular Assist System program during the first quarter of
fiscal 2005.

RESTRUCTURING CHARGES.
The Company recorded $0.4 million ($0.3 million after tax, or $0.01 diluted
earnings per share) of restructuring expenses in the first quarter of fiscal
2005 related primarily to accrued severance payments associated with its
consolidation of operations at its Winston-Salem, North Carolina and San
Antonio, Texas facilities into other existing manufacturing facilities and the
relocation of its European Distribution Center from Weesp, Netherlands to a more
centralized European location in the Limberg region of Belgium.

OPERATING INCOME.
Principally due to the above factors, operating income decreased in the first
quarter of fiscal 2005 by 10.2% to $19.4 million from $21.6 million in the
comparable prior year period.

OTHER EXPENSES (INCOME), NET.
Other expenses (income), net, was $0.3 million of income in the first quarter of
fiscal 2005 as compared to $0.2 million of expense in the same prior year
period. Other expenses (income), net, consist principally of interest expense
and foreign exchange gains and losses associated with the Company's direct sales
subsidiaries.

INCOME BEFORE INCOME TAXES.
As a result of the factors discussed above, income before income taxes decreased
during the first quarter of fiscal 2005 by 7.9% to $19.7 million from $21.4
million in the comparable prior year period. For the first quarter of each of
fiscal 2005 and 2004, the Company's effective income tax rate was 32.5%.

On October 22, 2004, the President signed The American Jobs Creation Act of 2004
(the "Act"). The Act included some of the most significant changes to corporate
taxation since 1996 and, among other things, eliminates the Extraterritorial
Income Regime (the "ETI") over a three-year phase out period beginning in 2005.
However, the phase out will still allow the Company to obtain a significant
percentage of the ETI benefit for fiscal 2005 and 2006 with a somewhat smaller
benefit for fiscal 2007. The ETI will be totally phased out by the Company's
2008 fiscal year end. Additionally, the Act provides for a deduction for U.S.
domestic manufacturers beginning

(19)

ARROW INTERNATIONAL, INC.

in the Company's fiscal year 2006. This new deduction begins at 3% of U.S.
domestic manufacturer's income for the Company's fiscal years 2006 and 2007,
increasing to 6% for the Company's fiscal years 2008 to 2010 and achieves its
maximum rate of 9% for the Company's fiscal years 2010 and beyond. While the
Company is not yet able to make an exact calculation of the overall effect of
these changes, management believes that the phased out repeal of the ETI benefit
during 2005 and 2006 and the phase in of the new manufacturing deduction benefit
from 2006 to 2011 should not have a material adverse effect on the Company's
effective tax rate, although it believes that the net effect will be less of an
income tax benefit to the Company for the remainder of fiscal 2005 and beyond.

NET INCOME.
Net income in the first quarter of fiscal 2005 decreased by 7.6% to $13.3
million from $14.4 million in the comparable fiscal 2004 period. As a percentage
of net sales, net income represented 11.8% in the three months ended November
30, 2004 compared to 14.0% in the same period of fiscal 2004.

PER SHARE INFORMATION.
Basic and diluted earnings per common share were $0.30 in the three months ended
November 30, 2004, down 9.1%, or $0.03 per share, from $0.33 in the comparable
prior year period. Weighted average shares of common stock outstanding used in
computing basic earnings per common share increased to 43,835,821 in the first
quarter of fiscal 2005 from 43,343,619 in the comparable prior year period
primarily a result of an increase in stock option exercises due to a higher
market price of the Company's stock relative to average outstanding option
exercise prices during the first quarter of fiscal 2005. Weighted average shares
of common stock outstanding used in computing diluted earnings per common share
increased to 44,526,195 in first quarter of fiscal 2005 from 43,982,988 in the
comparable prior year period primarily as a result of an increase in potentially
dilutive shares resulting from an increased share price and an increase in stock
option exercises for the reasons described above.

LIQUIDITY AND CAPITAL RESOURCES

OPERATING ACTIVITIES.
CASH FROM OPERATIONS. Arrow's primary source of funds continues to be cash
generated from operations, as shown in the Company's consolidated statements of
cash flows included in Item 1 of this report. For the three months ended
November 30, 2004, net cash provided by operations was $14.1 million, a decrease
of $10.0 million from the comparable prior year period, due primarily to the
timing of payments made to fund certain of the Company's pension plans and a
decrease in accounts payable and accrued liabilities net of the effect from its
acquisition of AB Medica during the quarter.

The Company made funding payments of $4.5 million in connection with the August
31, 2004 valuation of its pension plan in the first quarter of fiscal 2005, as
opposed to making $10.7 million of such payments in connection with its August
31, 2003 pension plan valuation in the fourth quarter of fiscal 2003.

ACCOUNTS PAYABLE. Accounts payable increased $3.6 million in the three months
ended November 30, 2004 primarily as a result of the Company's accrual of
payments of $3.5 million in connection with its acquisition of AB Medica during
the first quarter of fiscal 2005. In December 2004, the Company made $2.1
million of these accrued payments. In the three months ended November 30, 2003,
accounts payable increased by $3.9 million due primarily to the Company's
transition to a new accounts payable system during the first quarter of fiscal
2004 and the timing of payments to its vendors.

ACCOUNTS RECEIVABLE. Accounts receivable, measured in days sales outstanding
during the period, increased to 72 days at November 30, 2004 from 71 days at
August 31, 2004, due primarily to increased days sales outstanding in Greece, as
described below.

As of November 30, 2004, the Company had an accounts receivable balance from its
Greek customers of $6.2 million, of which approximately 90% is related to Greek
government-backed hospital customers. The days sales outstanding is currently
628 days, which is significantly higher than that of the Company's overall
November 30, 2004 average customer days sales outstanding of 72 days. However,
as previously reported, according to the Hellenic Association of Scientific and
Medical Equipment Suppliers, the average days sales outstanding for medical
equipment supply companies in the Greek market is approximately 420 days. The
Company's payment terms in this market are generally 45 days. The Company
believes that the government of Greece has been delaying payments due to its
government-backed hospitals, which has led to an increase in the Company's days
sales outstanding for its Greek customers. The Greek government has announced a
plan to resume its payments on its trade debt, which should allow its hospitals
to repay their outstanding balances to their vendors. The government of Greece
has initiated similar plans in the past to reduce delinquent trade debt, which
have resulted in the Company's realization of a material portion of outstanding
receivables following the implementation of those plans. As a result, the
Company currently believes that this situation will be resolved and that
ultimate collectibility of these receivables, net of discounts, is not a
significant risk. However, because the Company's assessment is based in part on
political factors beyond its control, the Company cannot assure that these
receivables will be collected or when they will be collected, and will continue
to evaluate their collectibility and establish reserves when and to the extent
necessary. As of November 30, 2004, the Company has recorded an allowance of
$0.4 million to reserve for both specifically identified potentially
uncollectible private Greek customer balances and an estimated amount for the
Greek government's discount on the Company's outstanding government-backed
hospital customer balance. The Company currently evaluates all of its trade
receivables on a regular basis, including those with its Greek customers, to
ensure that each receivable is recorded at net realizable value.

(20)

ARROW INTERNATIONAL, INC.

INVESTING ACTIVITIES.
Net cash used in the Company's investing activities increased to $12.2 million
in the three months ended November 30, 2004 from $4.3 million in the comparable
period of fiscal 2004, due primarily to the Company's acquisition, as further
discussed below, of AB Medica in the first quarter of fiscal 2005, costs
incurred in the first quarter of fiscal 2005 to expand the Company's finished
goods warehouse and distribution center in Asheboro, North Carolina, and
increased capital expenditures primarily in support of the Company's multi-year
capital investment plan, as further described below.

ACQUISITION OF AB MEDICA. In September 2004, the Company purchased certain
assets of one of its distributors in Italy, AB Medica S.p.A. ("ABM"), for a
total purchase price of approximately $8.4 million, subject to post-closing
adjustments, with additional amounts payable contingent upon the sales levels of
products under sales contracts purchased by the Company. ABM had been one of the
Company's distributors in Italy since 1982. The asset purchase agreement
includes the purchase of customer lists, distributorship rights, as well as the
inventory and specified tender contracts associated with the sale by ABM of the
Company's products. The Company began selling directly in Italy through its
subsidiary, Arrow Italy S.p.A., in the first quarter of fiscal 2005. As of
November 30, 2004, pursuant to the asset purchase agreement, the Company has
paid $4.9 million in cash and recorded a current liability of $3.5 million for
additional payment installments, of which $2.1 million was paid in December
2004. The purchase price for this acquisition did not exceed the estimated fair
value of the net assets acquired and, therefore, no goodwill has been recorded
by the Company in connection therewith. Intangible assets acquired of $5.4
million, consisting of customer lists and distributorship rights, are being
amortized over five years based on the anticipated period over which the Company
expects to benefit form the transaction. Included in the first quarter of fiscal
2005 was a $1.5 million charge, or $1.0 million against net income ($0.02
diluted earnings per share), for the step-up of inventory purchased from ABM.
The results of operations of this business are included in the Company's
consolidated financial statements from the date of acquisition. The purchase
price for this acquisition was allocated as follows:

(in millions)
Inventories $ 3.0
Intangible assets 5.4
---------
Total purchase price $ 8.4
=========

EARLY RETIREMENT PROGRAM. On October 27, 2004, the Company's Board of Directors
approved a voluntary early retirement program for all of the Company's salaried
exempt and non-exempt employees in its three locations in the Reading,
Pennsylvania area who attain age 57 or older and have at least five years of
service with the Company as of January 31, 2005. The program provides that each
such eligible employee who makes an election to retire from the Company on or
between November 10, 2004 and January 31, 2005 will (1) receive payments equal
to two weeks pay for each year of his or her service with the Company and a lump
sum payment of $20,000, (2) be treated as if such employee retired under the
salaried pension plan at his or her normal retirement date without any
additional years of service being credited, but without any reduction for early
commencement of benefits, and (3) have their stock options issued under the
Company's stock incentive plans, which are unvested as of the effective date of
his or her retirement, accelerated so as to vest and become fully exercisable as
of such date.

The Company presently anticipates that the maximum cash costs and pension
benefits of this program if all eligible employees were to participate in the
program, will be approximately $6.6 million, which will be included in
restructuring charges in the second quarter of fiscal 2005 as employee elections
under this program are received and the related costs are incurred. In addition,
the Company will incur a non-cash charge for accelerated vesting of stock
options held by participants in this program. The charge to earnings and credit
to additional paid in capital is determined at the date the participant signs
the election form committing him/herself to the voluntary early retirement
program and is calculated based on the difference between the closing price of
Arrow`s common stock on that date and the exercise price of the stock options
which become vested as of the date of the participant's retirement.

MULTI-YEAR CAPITAL INVESTMENT PLAN. As previously announced, the Company's Board
of Directors has authorized the initiation of a multi-year capital investment
plan to increase its worldwide manufacturing capacity and rationalize its
production operations. This plan is being initiated to support projections for
future growth and to integrate operations acquired in recent years. The first
phase of this effort will include the construction or acquisition of additional
manufacturing facilities in The Czech Republic and Chihuahua, Mexico, which
commenced in the first quarter of fiscal 2005. Based on preliminary estimates
received from its contractors, the Company currently anticipates the total cost
of this capacity increase to be between $20.0 million and $27.0 million over a
three-year period. In addition, the Company also anticipates spending between
$10.0 million and $15.0 million over the next three years for equipment related
to this expansion of its manufacturing capacity. As of November 30, 2004, the
Company had spent $0.9 million in connection with this capital investment plan.

As part of its plans to rationalize its operations in the United States, in
August 2004, the Company initiated the consolidation of its operations at its
Winston-Salem, North Carolina and San Antonio, Texas facilities into other
existing manufacturing facilities. The transitional work on this consolidation
has begun and is expected to continue into the third quarter of fiscal 2005. In
connection with this restructuring, the Company has accrued costs of $0.2
million, consisting primarily of severance payments in the first quarter of
fiscal 2005. Severance payments relate to approximately 53 employees primarily
in manufacturing at both facilities and are expected to be paid in fiscal 2005.
All other restructuring costs are expected to be paid over the remainder of
fiscal 2005 and fiscal 2006.

As part of its plans to rationalize its production operations in Europe, in
November 2004, the Company determined to move its European Distribution Center,
currently situated in Weesp, Netherlands, to a more centralized European
location in the Limberg region of Belgium in order to have better access to
existing carrier transportation networks and allow for more cost-competitive
expansion of its European operations in the future. The Company anticipates that
this re-location will be completed in the second quarter of fiscal 2005 and will
cost approximately $1.5 million. As of November 30, 2004, the Company has
accrued severance payments of $0.2

(21)

ARROW INTERNATIONAL, INC.

million related to this re-location, which amount represents total actual
restructuring costs incurred during the first quarter of fiscal 2005.

FINANCING ACTIVITIES.
Financing activities used $2.0 million of net cash in the three months ended
November 30, 2004 compared to $4.8 million in the same prior year period,
primarily as a result of a decrease in the Company's repayment of borrowings
under its revolving credit facility.

The Company's Board of Directors has authorized the repurchase of up to a
maximum of 4,000,000 shares under its share repurchase program. As of November
30, 2004, the Company had repurchased a total of 3,603,600 shares under this
program for approximately $57.5 million since the program's inception in March
1999. However, no shares were repurchased by the Company under the program (or
otherwise) in the three months ended November 30, 2004.

CREDIT FACILITIES.
To provide additional liquidity and flexibility in funding its operations, the
Company from time to time also borrows amounts under credit facilities and other
external sources of financing. At November 30, 2004, the Company had a revolving
credit facility providing a total of $65.0 million in available revolving credit
for general business purposes, of which $20.2 million was outstanding, all of
which is owed by its foreign subsidiaries. Under this credit facility, the
Company is required to comply with, among others, the following financial
covenants: maintain a ratio of total liabilities to tangible net worth (total
assets less total liabilities and intangible assets) of no more than 1.5 to 1
and a cash flow coverage ratio of 1.25 to 1 or greater; a limitation on certain
mergers, consolidations and sales of assets by the Company or its subsidiaries;
a limitation on the Company's and its subsidiaries' incurrence of liens; and a
requirement that the lender approve the incurrence of additional indebtedness
unrelated to the revolving credit facility when the aggregate principal amount
of such new additional indebtedness exceeds $75.0 million. At November 30, 2004,
the Company was in compliance with all such covenants. Failure to remain in
compliance with these covenants could trigger an acceleration of the Company's
obligation to repay all outstanding borrowings under this credit facility.

Certain other foreign subsidiaries of the Company had revolving credit
facilities totaling the U.S. dollar equivalent of $26.6 million, of which $7.7
million was outstanding as of November 30, 2004.

Interest rate terms for both U.S. and foreign bank credit facilities are based
on either bids provided by the lender or the prime rate, London Interbank
Offered Rates (LIBOR) or Certificate of Deposit Rates, plus applicable margins.
Certain of these borrowings, primarily those with U.S. banks, are due on demand.
Interest is payable monthly during the revolving credit period. Combined
borrowings under these facilities increased $1.9 million and $0.1 million during
the three months ended November 30, 2004 and November 30, 2003, respectively.

CONTRACTUAL OBLIGATIONS AND COMMERCIAL COMMITMENTS.
A summary of all of the Company's contractual obligations and commercial
commitments as of November 30, 2004 were as follows:

PAYMENTS DUE OR COMMITMENT
EXPIRATION BY PERIOD
------------------------------------------------------------------------
CONTRACTUAL OBLIGATIONS AND MORE
COMMERCIAL COMMITMENTS LESS THAN 1 - 3 3 - 5 THAN 5
(IN MILLIONS) TOTAL 1 YEAR YEARS YEARS YEARS
- -------------------------------------------------- ----------- ------------- ---------- ----------- -----------

Current maturities of long-term debt $ 3.0 $ 3.0 $ - $ - $ -
Operating leases 13.2 4.9 4.8 2.1 1.4
Purchase obligations(1) 31.3 31.3 - - -
Other long-term obligations 0.4 - 0.1 0.1 0.2
Lines of credit(2) 27.9 27.9 - - -
Standby letters of credit 2.1 2.1 - - -
----------- ------------- ---------- ----------- -----------

Total cash contractual obligations and
commercial commitments $77.9 $69.2 $4.9 $2.2 $1.6
=========== ============= ========== =========== ===========

(1) Includes open purchase orders primarily relating to purchases of raw
materials, equipment and certain consulting and information system
services.

(2) Includes short-term indebtedness of the Company and its subsidiaries
under various revolving credit facilities, as discussed above.

OUTLOOK.
Based upon its present plans, the Company believes that cash generated from its
operations and available credit resources, including its ability to extend
maturities of borrowings outstanding under its lines of credit in the ordinary
course consistent with past practice, will be adequate to repay current portions
of long-term debt, to finance currently planned capital expenditures, including
those pursuant to

(22)

ARROW INTERNATIONAL, INC.

the Company's recently announced multi-year capital investment plan discussed
above, and to meet the currently foreseeable liquidity needs of the Company.

During the periods discussed above, the overall effects of inflation and
seasonality on the Company's business were not significant.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company has disclosed in Note 1 to its consolidated financial statements and
in Management's Discussion and Analysis of Financial Condition and Results of
Operations included in its Annual Report on Form 10-K for the fiscal year ended
August 31, 2004 those accounting policies that it considers to be significant in
determining its results of operations and financial position. There have been no
material changes to the critical accounting policies previously identified and
described in the Company's 2004 Form 10-K. The accounting principles utilized by
the Company in preparing its consolidated financial statements conform in all
material respects to generally accepted accounting principles in the United
States of America.

The preparation of these consolidated financial statements requires the
Company's management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, revenues and expenses, as well as the disclosure
of contingent assets and liabilities at the date of its financial statements.
The Company bases its estimates on historical experience, actuarial valuations
and various other factors that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from
other sources. Some of those judgments can be subjective and complex and,
consequently, actual results may differ from these estimates under different
assumptions or conditions. While for any given estimate or assumption made by
the Company's management there may be other estimates or assumptions that are
reasonable, the Company believes that, given the current facts and
circumstances, it is unlikely that applying any such other reasonable estimate
or assumption would materially impact the financial statements.

NEW ACCOUNTING STANDARDS

The Financial Accounting Standards Board (FASB) issued Statement of Financial
Accounting Standards (SFAS) No. 151, "Inventory Costs, an Amendment of
Accounting Research Bulletin (ARB) No. 43, Chapter 4", in November 2004. This
statement amends the guidance in ARB No. 43 Chapter 4 "Inventory Pricing" to
clarify the accounting for abnormal amounts of idle facility expense, freight,
handling costs and wasted material. SFAS No. 151 requires that those items be
recognized as current period charges regardless of whether they meet the
criterion of "so abnormal." In addition, this statement requires that allocation
of fixed production overheads to the costs of conversion be based on the normal
capacity of the production facilities. The provisions of this statement will be
effective for inventory costs incurred during fiscal years beginning after June
15, 2005. The Company is currently evaluating the impact that this statement
will have on its financial statements.

The FASB issued "Share-Based Payment, an Amendment of SFAS No. 123 and 95", in
December 2004. This statement requires that the cost of all forms of
equity-based compensation granted to employees, excluding employee stock
ownership plans, be recognized in a company's income statement and that such
cost be measured at the fair value of the stock options. This statement replaces
the guidance in SFAS No. 123, Accounting for Stock-Based Compensation, and APB
No. 25, Accounting for Stock Issued to Employees. This statement will be
effective for financial statements relating to fiscal periods beginning after
June 15, 2005.

CAUTIONARY STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Certain statements contained in this report or in other written or oral
statements made from time to time by the Company may contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. Such statements may use words such as
"anticipate," "estimate," "expect," "believe," "plan," "may," "intend" and
similar words or terms. Although the Company believes that the expectations in
such forward-looking statements are reasonable, the Company cannot assure you
that such expectations will prove to have been correct. The forward-looking
statements are based upon a number of assumptions and estimates that, while
presented with specificity and considered reasonable by the Company, are
inherently subject to significant business, economic and competitive risks,
uncertainties and contingencies which are beyond the control of the Company, and
upon assumptions with respect to future business decisions which are subject to
change. Accordingly, the forward-looking statements are only an estimate, and
actual results will vary from the forward-looking statements, and these
variations may be material. The Company is not obligated to update any
forward-looking statement, but investors are urged to consult any further
disclosures the Company makes in its filings with the Securities and Exchange
Commission. Consequently, the inclusion of the forward-looking statements should
not be regarded as a representation by the Company of results that actually will
be achieved. Forward-looking statements are necessarily speculative in nature,
and it is usually the case that one or more of the assumptions in the
forward-looking statements do not materialize. Investors are cautioned not to
place undue reliance on the forward-looking statements. The Company cautions
investors that the factors set forth below, which are described in further
detail in Item 1. Business - "Certain Risks Relating to Arrow" in the Company's
Annual Report on Form 10-K for the fiscal year ended August 31, 2004 and in its
other filings with the Securities and Exchange Commission, could cause the
Company's results to differ materially from those stated in the forward-looking
statements. These factors include: (1) stringent regulation of the Company's
products by the U.S. Food and Drug Administration and, in some jurisdictions, by
state, local and foreign governmental authorities; (2) the highly competitive
market for medical devices and the rapid pace of product development and
technological change in this market; (3) pressures imposed by the health care
industry to reduce the cost or usage of medical products and services; (4)
dependence on patents and proprietary rights to protect the Company's trade
secrets and technology, and the need for litigation to enforce or defend these
rights; (5) risks associated with the Company's international operations; (6)
potential product liability risks inherent in the design, manufacture and
marketing of

(23)

ARROW INTERNATIONAL, INC.

medical devices; (7) risks associated with the Company's use of derivative
financial instruments; and (8) dependence on the continued service of key
members of the Company's management.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Financial Instruments:

During the three month periods ended November 30, 2004 and 2003, the percentage
of the Company's sales invoiced in currencies other than U.S. dollars was 24.7%
and 23.3%, respectively. In addition, a part of the Company's cost of goods sold
is denominated in foreign currencies. The Company enters into foreign currency
forward contracts and foreign currency option contracts, which are derivative
financial instruments, with major financial institutions to reduce the effect of
these foreign currency risk exposures, primarily on U.S. dollar cash inflows
resulting from the collection of intercompany receivables denominated in foreign
currencies and to hedge anticipated sales in foreign currencies to foreign
subsidiaries. Such transactions occur throughout the year and are probable, but
not firmly committed. Foreign currency forward contracts are marked to market
each accounting period, and the resulting gains or losses on these contracts are
recorded in Other (income) / expense of the Company's consolidated statements of
income. Gains and losses on these contracts are offset by changes in the U.S.
dollar value of the foreign currency denominated assets, liabilities and
transaction being hedged. The premiums paid on the foreign currency option
contracts are recorded as assets and amortized over the life of the option.
Other than the risk associated with the financial condition of the
counterparties, the Company's maximum exposure related to foreign currency
options is limited to the premiums paid. The total premiums authorized to be
paid in any fiscal year cannot exceed $1.0 million pursuant to the terms of the
Foreign Currency Management Policy Statement approved by the Company's Board of
Directors in fiscal 2001. Gains and losses on purchased option contracts result
from changes in intrinsic or time value. Both time value and intrinsic value
gains and losses are recorded in shareholders' equity (as a component of
comprehensive income) until the period in which the underlying sale by the
foreign subsidiary to an unrelated third party is recognized, at which point
those deferred gains and losses are recognized in net sales. By their nature,
all such contracts involve risk, including the risk of nonperformance by
counterparties. Accordingly, losses relating to these contracts could have a
material adverse effect upon the Company's business, financial condition and
results of operations. Based upon the Company's knowledge of the financial
condition of the counterparties to its existing foreign currency forward
contracts, the Company believes that it does not have any material exposure to
any individual counterparty. The Company's policy prohibits the use of
derivative instruments for speculative purposes. The Company expects to continue
to utilize foreign currency forward contracts to manage its exposure, although
there can be no assurance that the Company's efforts in this regard will be
successful. As of November 30, 2004, outstanding foreign currency forward
contracts totaling the U.S. dollar equivalent of $11.1 million mature at various
dates through February 2005. As of November 30, 2004, the Company had no foreign
currency option contracts outstanding. The Company expects to continue to
utilize foreign currency forward contracts and foreign currency option contracts
to manage its exposure, although there can be no assurance that the Company's
efforts in this regard will be successful.

The Company's exposure to credit risk consists principally of trade receivables.
Hospitals and international dealers account for a substantial portion of trade
receivables and collateral is generally not required. The Company believes its
risk associated with this concentration is limited due to its on-going credit
review procedures.

At November 30, 2004, the Company had foreign currency forward contracts to sell
foreign currencies which mature at various dates through February 2005. The
following table identifies foreign currency forward contracts to sell foreign
currencies at November 30, 2004 and August 31, 2004:

November 30, 2004 August 31, 2004
Notional Fair Market Notional Fair Market
Amounts Value Amounts Value
--------------- ------------------- ---------------- ------------------

Foreign currency: (U.S. Dollar Equivalents)
Japanese yen $ 951 $ 974 $ - $ -
Euro 7,891 7,962 14,643 14,603
Mexican peso 697 701 1,379 1,393
African rand - - 445 450
--------------- ------------------- ---------------- ------------------
$ 9,539 $ 9,637 $ 16,467 $ 16,446
=============== =================== ================ ==================

(24)

ARROW INTERNATIONAL, INC.

At November 30, 2004, the Company also had foreign currency forward contracts to
buy foreign currencies which mature at various dates through December 2004. The
following table identifies forward exchange contracts to buy foreign currencies
at November 30, 2004 and August 31, 2004:

November 30, 2004 August 31, 2004
Notional Fair Market Notional Fair Market
Amounts Value Amounts Value
--------------- ------------------- ---------------- ------------------

Foreign currency: (U.S. Dollar Equivalents)
Czech koruna $ 641 $ 662 $ 3,031 $ 2,996
Euro - - 7,305 7,306
Mexican peso 879 879 703 702
--------------- ------------------- ---------------- ------------------
$ 1,520 $ 1,541 $ 11,039 $ 11,004
=============== =================== ================ ==================

From time to time, the Company purchases foreign currency option contracts to
hedge anticipated sales in foreign currencies to foreign subsidiaries. The
option premiums paid are recorded as assets and amortized over the life of the
option. Other than the risk associated with the financial condition of the
counterparties, the Company's maximum exposure related to foreign currency
options is limited to the premiums paid. The total premiums authorized to be
paid in any fiscal year cannot exceed $1.0 million pursuant to the terms of the
Foreign Currency Management Policy Statement as approved by the Company's Board
of Directors in fiscal 2001. Gains and losses on purchased option contracts
result from changes in intrinsic or time value. Both time value and intrinsic
value gains and losses are recorded in shareholders' equity (as a component of
comprehensive income / (expense)) until the period in which the underlying sale
by the foreign subsidiary to an unrelated third party is recognized, at which
point those deferred gains and losses are recognized in net sales. During the
three months ended November 30, 2004 and 2003, the Company did not recognize any
time value or intrinsic value losses against net sales. At November 30, 2004,
the Company did not have any unrealized holding losses related to these foreign
currency option contracts. The Company had no foreign currency option contracts
outstanding at November 30, 2004 and August 31, 2004.

Item 4. Controls and Procedures

An evaluation was performed under the supervision and with the participation of
the Company's management, including its Chief Executive Officer, or CEO, and
Chief Financial Officer, or CFO, of the effectiveness of the Company's
disclosure controls and procedures as of November 30, 2004. Based on that
evaluation, the Company's management, including its CEO and CFO, have concluded
that the Company's disclosure controls and procedures are effective to ensure
that information required to be disclosed in the reports that the Company files
or submits under the Securities Exchange Act of 1934 is recorded, processed,
summarized and reported within the time periods specified in the Securities and
Exchange Commission's rules and forms. There have been no significant changes in
the Company's internal controls over financial reporting or in other factors
identified in connection with this evaluation that occurred during the three
months ended November 30, 2004 that have materially affected, or are reasonably
likely to materially affect, the Company's internal control over financial
reporting. The Company is responding to observations made in connection with the
FDA's inspection of the Company's facilities relating to its NEOCare product
line, some of which related to the Company's internal controls relating to the
NEOCare product line, which may have a future impact on the Company's internal
controls over financial reporting.

PART II OTHER INFORMATION

Item 5. Other Information

RETIREMENT OF LONG-SERVING EXECUTIVE OFFICERS. On October 29, 2004, the Company
announced the retirement of its President and Chief Operating Officer, Philip B.
Fleck, effective as of December 31, 2004, and other changes in the composition
of some of its executive officers. Mr. Fleck served in management capacities
with Arrow and its predecessor company for over 33 years and made a major
contribution to the Company's success. In addition, Paul L. Frankhouser, the
Company's Executive Vice President - Global Business Development, recently
announced his retirement from the Company, effective as of January 31, 2005. Mr.
Frankhouser served in management capacities with Arrow and its predecessor
company for over 41 years and made a major contribution to the Company's
success.

QUALIFIED TRADING PLANS. The Company's President and Chief Operating Officer,
Philip B. Fleck, and two of the Company's directors, former executive officers
and founders, Marlin Miller, Jr. and John H. Broadbent, Jr., have informed the
Company that, in order to diversify their investment portfolios while avoiding
conflicts of interest or the appearance of any such conflict that might arise
from their ongoing service to the Company, in the first quarter of fiscal 2005
they established written plans in accordance with SEC Rule 10b5-1 for gradually
liquidating a portion of their personal holdings of the Company's common stock.
Each of these plans provide for weekly

(25)

ARROW INTERNATIONAL, INC.

or other periodic stock sales and do not prohibit Mr. Fleck, Mr. Miller or Mr.
Broadbent from executing additional transactions with respect to the Company's
common stock.

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits

See Exhibit Index on page 28 for a list of the Exhibits
filed as part of this report.

(b) Reports on Form 8-K:

o Current Report on Form 8-K, dated September 29,
2004, reporting under Item 2.02. Results of
Operations and Financial Condition, announcing
the Company's fourth quarter fiscal 2004
earnings.

o Current Report on Form 8-K, dated October 27,
2004, reporting under Item 1.01. Entry into a
Material Definitive Agreement; Item 5.02.
Departure of Director or Principal Officers;
Election of Directors; Appointment of Principal
Officers; and Item 5.03. Amendments to Articles
of Incorporation or By-laws; Changes in Fiscal
Year, relating to the Company's approval of a
new early retirement program, the retirement of
the Company's President and Chief Operating
Officier and certain amendments to the Company's
By-laws.

o Current Report on Form 8-K, dated December 3,
2004, reporting under Item 8.01. Other Events,
announcing the Company's voluntary nationwide
recall of all its NEO?PICC(R) 1.9 FR
Peripherally Inserted Central Catheters.

o Current Report on Form 8-K, dated December 20,
2004, reporting under Item 2.02. Results of
Operations and Financial Condition, announcing
the Company's first quarter fiscal 2005
earnings.

(26)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

ARROW INTERNATIONAL, INC.
(Registrant)

Date: January 10, 2005 By: /s/ Frederick J. Hirt
--------------------------------
(signature)

Frederick J. Hirt
Chief Financial Officer and
Senior Vice President of Finance
(Principal Financial Officer and
Chief Accounting Officer)

(27)

EXHIBIT INDEX

EXHIBIT DESCRIPTION
NUMBER OF EXHIBIT METHOD OF FILING
- ------ ---------- ----------------

31.1 Rule 13a-14(a)/15d-14(a) Certification of the Furnished herewith
Chief Executive Officer

31.2 Rule 13a-14(a)/15d-14(a) Certification of the Furnished herewith
Chief Financial Officer

32.1 Section 1350 Certification of the Chief Furnished herewith
Executive Officer

32.2 Section 1350 Certification of the Chief Furnished herewith
Financial Officer

(28)